Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Puretech Health PLC    PRTC   GB00BY2Z0H74

PURETECH HEALTH PLC (PRTC)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
Most relevant news about PURETECH HEALTH PLC
04/10PURETECH HEALTH : Akili Digital Medicine Technology Platform Granted Multiple Pa..
BU
04/10PURETECH HEALTH : Sonde Health Announces U.S. and Australian Patent Issuances Br..
BU
04/09PURETECH HEALTH : Commense Appoints Edward J. “Tad” Stewart as Presi..
BU
04/03PURETECH HEALTH : Alivio Technology for Treating Inflammatory Diseases via Targe..
BU
03/01GELESIS : Raises $30 Million to Prepare for Potential Launch of Lead Product
BU
01/29RESTORBIO : BioCentury - resTORbio raises $85M IPO
AQ
01/26PURETECH HEALTH : Affiliate resTORbio Announces Pricing of Initial Public Offeri..
PU
01/03PURETECH HEALTH : Affiliate resTORbio Adds Lynne Sullivan, Biogen Senior Vice Pr..
PU
01/03PURETECH HEALTH : resTORbio Appoints Lynne Sullivan to Its Board of Directors
BU
01/02PURETECH HEALTH : Affiliate resTORbio Files Public Registration Statement for Pr..
PU
2017PURETECH HEALTH : Affiliate Entrega to Receive $5 Million for Eli Lilly Collabor..
DJ
2017PURETECH HEALTH : Entrega To Receive $5 Million Investment from Lilly To Advance..
PU
2017ENTREGA : To Receive $5 Million Investment from Lilly To Advance Proprietary Ora..
BU
2017PURETECH HEALTH : Vedanta Biosciences Granted Four New US Patents Expanding Cove..
PU
2017VEDANTA BIOSCIENCES : Granted Four New U.S. Patents Expanding Coverage for Compo..
BU
2017PURETECH HEALTH : resTORbio Appoints Paul Fonteyne to Its Board of Directors
BU
2017PURETECH HEALTH : Affiliate resTORbio Adds Paul Fonteyne, CEO of Boehringer Inge..
PU
2017PURETECH HEALTH : Microbiome Programme Advances into a Phase 1a/1b Clinical Tria..
PU
2017VEDANTA BIOSCIENCES : Announces Initiation of Phase 1a/1b Trial for New Drug Cla..
BU
2017PURETECH HEALTH : resTORbio Files Confidential Submission of Draft Registration ..
PU
2017PURETECH HEALTH : resTORbio Files Confidential Submission of Draft Registration ..
BU
2017PURETECH HEALTH : Akili Achieves Primary Endpoint in Pivotal Study of Investigat..
PU
2017PURETECH HEALTH : Akili Achieves Primary Efficacy Endpoint in Pediatric ADHD Piv..
BU
2017PURETECH HEALTH : resTORbio Raises $40 Million from Leading Biotech and Institut..
PU
2017PURETECH HEALTH : Vedanta Biosciences Expands Clinical Translational Collaborati..
PU
2017VEDANTA BIOSCIENCES : Expands Network of Clinical Collaborations Supporting Deve..
BU
2017PURETECH HEALTH : to Present at Piper Jaffray 2017 Healthcare Conference
BU
2017PURETECH HEALTH : resTORbio Advances Immunotherapy Candidate for Aging-Related C..
PU
2017PURETECH HEALTH : to Present at Jefferies 2017 Healthcare Conference in London
BU
2017PURETECH HEALTH : Vedanta Biosciences Awarded $5.4 Million Grant from Combating ..
PU
2017VEDANTA BIOSCIENCES : Awarded Up To $5.4 Million from CARB-X to Accelerate Devel..
BU
2017PURETECH HEALTH : Vedanta Licenses Microbiome-Derived Immuno-Oncology Product Ca..
PU
2017VEDANTA BIOSCIENCES : to Advance Cancer Immunotherapy Candidates Based on Microb..
BU
2017GELESIS : 100 Achieves Significant Weight Loss with Excellent Safety Profile in ..
BU
2017PURETECH HEALTH : Gelesis Reports Significant Weight Loss with Excellent Safety ..
PU
2017PURETECH HEALTH : Notes US Patent Issuance Broadly Covering Methods of Assessing..
PU
2017PURETECH HEALTH : Notes U.S. Patent Issuance Broadly Covering Methods of Assessi..
BU
2017PURETECH HEALTH : Exclusively Licenses Glyph Technology from Monash University t..
BU
2017PURETECH HEALTH PLC : half-yearly earnings release
2017PURETECH HEALTH : Notice of Half-Yearly Results
PU
2017PURETECH HEALTH : Presents Data Supporting Treatment Approach for Interstitial C..
BU
2017PURETECH HEALTH : Gelesis Announces Last Patient Visit in the Pivotal Gelesis100..
PU
2017PURETECH HEALTH : Gelesis Announces Last Patient Out in the Pivotal Gelesis100 W..
BU
2017PURETECH HEALTH : Akili Appoints Former Cubist CEO, Rob Perez, as Executive Chai..
PU
2017PURETECH HEALTH : Former Cubist CEO, DreamWorks Interactive CEO, and Google Chie..
BU
2017PURETECH HEALTH : Vedanta Biosciences Granted U.S. Patent Broadly Covering Metho..
PU
2017VEDANTA BIOSCIENCES : Granted U.S. Patent Broadly Covering Methods of Treatment ..
BU
2017PURETECH HEALTH : to Present at Jefferies 2017 Global Healthcare Conference
BU
2017PURETECH HEALTH : Karuna to Present Tolerability Proof-of-Concept Data for KarXT..
PU
2017KARUNA PHARMACEUTICALS : to Present KarXT Tolerability Proof-of-Concept Data for..
BU
2017PURETECH HEALTH : Sync Project Announces New Investors and Accelerates Developme..
PU
2017PURETECH HEALTH : Sync Project Announces New Investors and Accelerates Developme..
BU
2017PURETECH HEALTH : Vedanta Biosciences Granted Three New U.S. Patents for Therape..
PU
2017PURETECH HEALTH : Vedanta Biosciences Granted Three U.S. Patents Broadly Coverin..
BU
2017PURETECH HEALTH : Results of Annual General Meeting
PU
2017PURETECH HEALTH : Announces Licensing Agreement between Commense and the Univers..
PU
2017PURETECH HEALTH : Announces Initiation of Phase 2b mTORC1 Inhibitors Study in El..
BU
2017PURETECH HEALTH : Announces Licensing Agreement between Commense and the Univers..
BU
2017GELESIS : Announces €2.9 Million Award from Italian Ministry of Economic Develop..
BU
2017CORRECT : PureTech Health's Chowrira Buys 34,000 Shares
AQ
2017DIRECTOR DEALINGS : PureTech Health's Chowrira Buys 34,000 Shares
AQ
2017PURETECH HEALTH : resTORbio Appoints Joan Mannick, M.D., as Chief Medical Office..
PU
2017PURETECH HEALTH : resTORbio Appoints Joan Mannick, M.D., as Chief Medical Office..
BU
2017PURETECH HEALTH : Advances New Programme Targeting Immunosuppressive Gamma Delta..
PU
2017PURETECH HEALTH : Advances New Program Targeting Immunosuppressive Gamma Delta T..
BU
2017PURETECH HEALTH : Announces Annual Results for Year Ended 31 December 2016
PU
2017PURETECH HEALTH : Akili Announces Results from a Project EVOTM Pilot Study Demon..
PU
2017PURETECH HEALTH : Akili Announces Results from Pilot Study Showing Treatment wit..
BU
2017PURETECH HEALTH : Announces Licensing and Equity Agreement with Novartis to Adva..
PU
2017PURETECH HEALTH : Announces Licensing and Equity Agreement with Novartis to Adva..
BU
2017PURETECH HEALTH : Notice of Results - FYE 2016
PU
2017PURETECH HEALTH : Appoints Bharatt Chowrira, Ph.D., J.D., as President and Chief..
PU
2017PURETECH HEALTH : Appoints Bharatt Chowrira, Ph.D., J.D., as President and Chief..
BU
2017PURETECH HEALTH : to Present at the Cowen and Company 37th Annual Health Care Co..
BU
2017PURETECH HEALTH : Appoints Atul Pande as Chief Medical Officer
DJ
1  2Next
Financials ($)
Sales 2018 3,30 M
EBIT 2018 -131 M
Net income 2018 -68,3 M
Finance 2018 95,5 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 136x
EV / Sales 2019 360x
Capitalization 543 M
Chart PURETECH HEALTH PLC
Duration : Period :
Puretech Health PLC Technical Analysis Chart | PRTC | GB00BY2Z0H74 | 4-Traders
Technical analysis trends PURETECH HEALTH PLC
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 3,63 $
Spread / Average Target 62%
EPS Revisions
Managers
NameTitle
Daphne Zohar Chief Executive Officer & Executive Director
Bharatt M. Chowrira President, Chief Business & Strategy Officer
Joichi Ito Non-Executive Chairman
Stephen Muniz Chief Operations Officer, Secretary & Director
Eric Elenko Chief-Research & Strategy
Sector and Competitors
1st jan.Capitalization (M$)
PURETECH HEALTH PLC6.67%543
CELLTRION, INC.--.--%31 274
IQVIA HOLDINGS INC0.92%20 671
LONZA GROUP-8.28%18 497
NEKTAR THERAPEUTICS56.92%14 892
INCYTE CORPORATION-25.54%14 841